-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA APPROVES GENENTECH’S TECENTRIQ IN COMBINATION WITH A FLUOROPYRIMIDINE AND OXALIPLATIN FOR THE ADJUVANT TREATMENT OF A CERTAIN TYPE OF STAGE III COLON CANCER

Reuters·10/09/2026 05:01:11